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Abstract:  The  classification  of  colorectal  cancers  (CRC)  is  currently  based  largely  on 
histologically determined tumour characteristics, such as differentiation status and tumour 
stage,  i.e.,  depth  of  tumour  invasion,  involvement  of  regional  lymph  nodes  and  the 
occurrence of metastatic spread to other organs. These are the conventional prognostic 
factors for patient survival and often determine the requirement for adjuvant therapy after 
surgical resection of the primary tumour. However, patients with the same CRC stage can 
have very different disease-related outcomes. For some, surgical removal of early-stage 
tumours leads to full recovery, while for others, disease recurrence and metastasis may 
occur regardless of adjuvant therapy. It is therefore important to understand the molecular 
processes  that  lead  to  disease  progression  and  metastasis  and  to  find  more  reliable 
prognostic  markers  and  novel  targets  for  therapy.  This  review  focuses  on  cell  surface 
proteins  that  correlate  with  tumour  progression,  metastasis  and  patient  outcome,  and 
discusses some of the challenges in finding prognostic protein markers in CRC.  
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1. Introduction 
Colorectal cancer (CRC) is a cancer of epithelial origin, localized to the large intestine and rectum. 
It  is  one  of  the  most  common  cancers  and will occur at  some stage in  approximately 5% of the 
population of the western world. The conventional prognostic factors for patient survival are histologic 
tumour grade (differentiation) and tumour stage (TNM, tumors/nodes/metastases, stages I–IV) [1,2], 
which is based on depth of tumour invasion, involvement of regional lymph nodes and metastatic 
spread  to  other  organs  [3].  If  metastasis  has  occurred,  patient  5-year  survival  after  surgery  falls 
dramatically from 90% to less than 10% [4]. It is therefore important to increase our understanding of 
the  molecular  changes  leading  to  development,  spread  and  metastasis  of  CRC  and  to  identify 
potentially prognostic and predictive markers for the disease.  
Despite  the  discovery  of  a  range  of  intra-  and  extra-cellular  protein  biomarkers  for  CRC  and 
continuing efforts to discover potentially prognostic and predictive markers using various approaches 
[5–12], the translation of this increasing volume of differential proteomic data into patient care remains 
a major challenge. This is partly due to the heterogeneous nature of CRC [13,14] and the complexity of 
processes involved in its development and spread, but also to challenges presented in detecting and 
characterising glycoproteins and low abundance proteins [15,16] in complex mixtures. In addition, 
validation of candidate proteins as prognostic markers is time-consuming and expensive, and recent 
critical reviews of differentially expressed proteins from comparative proteomic studies have suggested 
that some reported proteins may be associated with general cellular stress responses, rather than being 
disease-specific biomarkers [17,18]. The development of a reliable assay for determining prognosis 
and guiding post-surgical therapy therefore remains elusive.  
The metastatic potential of CRC may be already encoded in the primary tumour [19], and molecular 
staging using a classifier based on 43 genes has identified patient prognosis more accurately than the 
traditional clinical staging, particularly for intermediate stage II and III patients [20]. It may be possible 
to identify disease signatures based on protein expression profiles in primary CRC tissues that reflect 
potential  for  disease  progression  and  metastasis,  and  subsequently  use  these  signatures  to  predict 
patient recovery and survival after surgical removal of the primary CRC tissue. With this goal in mind, 
we have developed a 122-antibody microarray (DotScan™ CRC microarray; Medsaic Pty Ltd, NSW, 
Australia)  for  immunophenotyping  live  cells  from  fresh  disaggregated  CRC  tissues  [21,22]. 
Microarrays prepared as 10 nl antibody dots on nitrocellulose-coated microscope slides (FAST; Grace 
Bio-labs,  Bend,  OR,  USA)  bind  cells  with  corresponding  surface  molecules,  producing  a  binding 
pattern that reflects the surface immunophenotype of the mixed cell population. Bound cells are then 
fixed to the microarray with formalin, and specific sub-populations are profiled by multiplexing with 
mixtures of soluble fluorescently-labelled antibodies. Hierarchical clustering of binding patterns for 
these sub-populations of cells yields patient clusters that may correlate with disease stage, tumour 
invasiveness,  differentiation,  drug  susceptibility  or  patient  outcome.  This  antibody-based  multiple Int. J. Mol. Sci. 2011, 12                       
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marker  approach  has  already  been  validated  for  the  classification  of  a  range  of  common  human 
leukaemias and lymphomas [23].  
The evolution of CRC from an adenomatous polyp to metastatic disease is dependent not only on 
progressive  accumulation  of  genetic  and  epigenetic  abnormalities  [24],  but  also  on  the  complex 
interactions of different sub-populations of cells within the tumour microenvironment (cancer cells, 
normal stromal cells, infiltrating leukocytes and the soluble factors they produce) [25]. The importance 
of  cell  surface  molecules  for  cell-cell  adhesion  and  communication  between  cancer  cells  and  
non-malignant cells has been recently reviewed [26,27], and the significance of signalling pathways 
involved in CRC progression as a result of these interactions has also been described [28–32]. Since 
many drugs used in cancer therapy target cell membrane proteins [33], this review seeks to summarise 
current knowledge on cell surface molecules that may serve as therapeutic targets, have prognostic 
significance or provide important information about the invasive, metastatic and proliferative potential 
of  cancers  of  the  large  intestine  and  rectum.  Antibodies  to  some  of  these  proteins  have  been 
incorporated into the current DotScan™ CRC antibody microarray; others could be added in the future. 
Readers  are  also  referred  to  several  previous  reviews  on  markers  of  metastasis  and  prognosis  in  
CRC [34,35]. 
2. Tumour Stroma 
Recently,  the importance of the tumour microenvironment  for the development,  promotion  and 
spread of cancer has become clear [36], and the potential for using tumour stroma-derived biomarkers 
in prognostication and therapy of cancer patients has been realised [37]. The stroma consists of the 
non-malignant cells of the tumour―fibroblasts, infiltrating leukocytes and cells of the blood vessels. 
However, despite experimental evidence for the importance of tumour stroma for cancer development 
and  progression,  clinical  applications  for  stromal  biomarkers  remain  limited.  Down-regulation  of  
TGF-beta receptor 2 (TGF-β-R2) in tumour-associated stroma correlates with a worse prognosis [38], 
while  expression  of  platelet-derived  growth  factor  receptor  (PDGFR)  on  stromal  cells  correlates 
directly with metastatic potential and advanced-stage disease in CRC [39,40]. 
Stromal CXCR4 (CD184) and CXCL12 expression is associated with distant recurrence and poor 
prognosis in rectal cancer after chemotherapy [41]. Patients whose colon tumours have high levels of 
stromal fibroblast activation protein (FAP) are more likely to have aggressive disease progression and 
potential development of metastases or recurrence [42]. Urokinase receptor (uPAR; CD87) expression 
in  stromal  fibroblasts  has  been  implicated  in  the  occurrence  of  haematogenous  metastasis 
(dissemination via the blood) of CRC [43]. The presence of high levels of stroma and down-regulation 
of Deleted in Pancreatic Cancer 4 (SMAD4) predict worse survival for early-stage CRC patients [44]. 
Expression of CD10 (a cell surface metalloprotease) on stromal cells adjacent to cancer cells within the 
area of invasive growth is significantly higher in invasive CRC than in non-invasive CRC or adenomas 
[45].  The  stromal  expression  of  CD10  also  appears  to  be  significantly  associated  with  abnormal 
accumulation of nuclear p53 in tumour cells and a larger tumour size, suggesting that CD10 expression 
may contribute to tumour invasion and possibly facilitate metastasis [45]. 
Thrombospondin-1  (TSP-1),  mainly  localised  in  fibroblasts  of  the  CRC  stroma  [46],  has  been 
considered as an important negative-regulator of tumour angiogenesis. TSP-1 expression in primary Int. J. Mol. Sci. 2011, 12                       
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CRC tumours has been correlated inversely with metastatic potential and prognosis [47–51]. In CRC 
liver  metastases,  however,  TSP-1  expression  has  been  linked  to  significantly  poorer  survival, 
suggesting that TSP-1 in liver metastases may have an alternative mode of action, facilitating tumour 
invasion rather than acting as an anti-angiogenic growth factor [51]. 
3. Inflammation and Infiltrating Leukocytes 
Inflammatory reactions in tumours can have a positive influence on survival [52,53] or alternatively 
can  be  associated  with  development  of  metastases  and  disease  progression  [54–56].  The  role  of 
tumour-associated  macrophages  (TAM)  in  tumourigenesis  is  complex  because  TAMs  can  either 
prevent  or  promote  tumour  development.  While  Forssell  et  al.  [52]  showed  that  a  dense  TAM 
infiltration  at  the  tumour  front  positively  influenced  prognosis  in  colon  cancer,  strong  
pro-tumourigenic effects of TAMs in CRC have also been reported [54–57]. It has been suggested that 
the balance between pro- and anti-tumourigenic properties of TAMs may depend on their interaction 
with cancer cells, other stromal cells, and the tumour microenvironment [54] or be influenced by the 
degree of cell-cell contact [52].  
The presence of high numbers of mature CD208+ infiltrating dendritic cells (DC) in the tumour 
epithelium has been associated with shorter overall patient survival, while patients with high numbers 
of CD1a+ DCs in the advancing margin of the tumour appear to have a shorter disease-free survival 
[58]. These findings are controversial, however, as a strong correlation has also been found between 
the presence of DCs together with high density T-cells and no detectable metastases [59] and better 
patient survival [60]. 
The presence of large numbers of tumour infiltrating lymphocytes (TILs) at the invasive tumour 
front has generally been associated with a good prognosis for CRC patients [61–64]. Patients with high 
levels of CD3+, CD8+, CD25+, CD45RO+ or CD95L(CD154)+ TILs appear to have a better clinical 
course [65–69] than those with low levels, particularly in early disease stages [70]. The importance of 
the  intra-tumoural  location,  immunophenotype  and  density  of  these  infiltrates  has  been  
demonstrated [71–73]. 
It has been shown that CD3+ TILs located in the tumour stroma are not as strong predictors of 
prognosis as T-cells located within cancer cell nests (clusters), consistent with the requirement for 
direct contact between target and effector cells [71–74]. In addition, although the presence of high 
density CD3+ TILS in primary tumours has been associated with good prognosis in patients with 
lymph node-negative CRC, there was no significant correlation between high density CD3+ TILs and 
absence of post-surgical metastases in patients with lymph node-positive CRC [75]. 
Patients with T-cells showing low CD4+/CD8+ ratios have a better clinical course than those with 
high ratios [59,76]. The infiltration of cancer cell nests by CD8+ T-cells has been associated with 
better survival [67], supporting the importance of activated cytotoxic CD8+ T-cells in the anti-tumour 
response to CRC [77,78].  
The  better  overall  survival  of  CRC  patients  with  high  infiltrates  of  CD3+  (total)  and  CD8+ 
(cytotoxic) T-cells within cancer cell nests, was recently confirmed [70]. Interestingly, however, this 
correlation was not significant for the rectal cancer patient sub-group when it was analysed separately 
from the colon cancer group. Furthermore, in patients whose tumours were positive for microsatellite Int. J. Mol. Sci. 2011, 12                       
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instability (MSI+), a hallmark of DNA mismatch repair (MMR) deficiency [79], no association was 
found between high levels of activated cytotoxic T-cells and a favourable prognosis. Although these 
findings are in agreement with those of several other groups, they are in conflict with a number of 
studies  in  which  high  infiltrates  of  CD8+  TILs  correlated  with  good  prognosis  regardless  of  
MSI-status [70].  
Marked infiltration of CD8+ and CD57+ natural killer (NK) or NK-like T-cells in the advancing 
tumour margin has also been associated with longer disease-free survival, and this was most evident in 
MSI+ tumours [80]. Metastatic spread of CRC is associated with decreased NK-cell activity [81], but it 
remains speculative whether decreased NK-cell activity precedes the development of metastases and 
may therefore be prognostic. 
Koch  et  al.  [82]  reported  strong  and  significant  enrichment  for  CD4+  T  helper  cells  in  CRC 
compared to corresponding normal mucosa, i.e., decreased proportions of CD8+ cells in total T-cell 
populations of CRC. However, a significantly higher proportion of the CD8+ TILs in CRC expressed 
markers  of  activation  (CD69+)  and  cytotoxic  activity  (CD107a+)  compared  with  normal  mucosa. 
Significantly, the proportion of activated CD8+ TILs decreased with tumour stage [82]. 
If a tumour exhibits a high T-cell infiltrate, the prognosis for patients with strong tumour expression 
of major histocompatibility antigen class I (MHC 1) is better than for those who have weak MHC 1 
expression  [74],  because  the  immune  response  mounted  against  the  tumour  cells  is  weaker  in  
these patients. 
TILs recovered from primary tumours showing no sign of metastasis differ immunophenotypically 
from those showing early signs of tumour metastasis (presence of vascular emboli, lymphatic invasion 
and perineural infiltration). Using flow cytometry, Pages et al. [68] found that TILs from tumours with 
no sign of metastasis showed higher expression of markers of cell adhesion (CD62L, CCR7, CD103, 
CD49d  and  CXCR3),  activation  (HLA-DR,  CD98,  CD80,  CD86  and  CD134)  and  differentiation 
(CD45RO, CD45RA, CD27, CD28, CCR7 and CD127). Primary CRC tumours without early signs of 
metastatic  invasion  such  as  vascular  emboli  (i.e.,  infiltration  of  cancer  tissue  into  blood  vessels) 
presented with significant increases in T-cell sub-populations from early memory (CD45RO+CCR7-
CD28+CD27+)  to  effector  memory  CD8+  T-cells  (CD45RO+CCR7-CD28+CD27-).  Using 
immunohistochemistry-based tissue microarray analysis of 415 tumours, they confirmed that a high 
density of memory T-cells (CD3+CD45RO+) in the primary tumour correlated with the absence of 
early signs of metastatic invasion, confirming previous findings [83]. In a comparison of patients with 
high T-cell infiltration, primary tumours from patients with metastases had significantly decreased 
densities  of  CD8+  T-cells  and  effector  memory  T-cells  (CD27-CD45RA-)  than  patients  without 
metastases [59].  
The surface antigen expression of total TILs differs from that of T-cells in peripheral blood, with 
markedly lower expression of CD29, CD49d and CD49f, and slightly higher expression of CD49a and 
CD49b [84]. CD11a and CD18 are reduced on CD8+, but not CD4+, sub-populations [84]. TILs also 
differ from lymphocytes within normal colon interstitium by lacking CD28, CD56, CD98 and CD154 
[85] and showing altered expression of CD3, CD29, LFA-1 (CD11a/CD18) and LFA-3 (CD58) [86].  
The  function  and  relative  importance  of  different  CD4+  sub-populations  in  CRC  is  still  only 
partially understood. Although CD4+ TILs are observed in CRC [59,80,87], the density of this sub-Int. J. Mol. Sci. 2011, 12                       
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population  has  shown  little  prognostic  value  in  CRC  to  date,  and  is  not  significantly different  in 
primary tumours of patients with metastatic or non-metastatic disease [59]. A high density of CD4+ 
TILs in CRC liver metastases has correlated with poorer patient outcome [63].  
Recent attention has focussed on CD4+CD25+ regulatory T-cells (Treg), which are characterised by 
expression of nuclear transcription factor forkhead box P3 (FoxP3). The CD3+ / FOXP3+ cell ratio 
[88] and the CD8+ / FOXP3+ cell ratio [89] are both predictive markers for disease-free survival time 
and overall survival time in patients with CRC, supporting the down-modulatory role of Treg in the 
presence of protective cytotoxic T-cells. Controversially, the presence of a high density of FoxP3+ 
Treg in CRC has also been associated with improved survival in stage II and stage III CRC patients 
[66,83]  and  in  relapsed  CRC  patients  undergoing  chemotherapy  or  chemoimmunotherapy  [90]. 
Although this result is unexpected and counterintuitive, it has been suggested that the increase in Tregs 
in tumour tissue may represent a feedback response to a pre-existing cancer cell-directed immune 
response  [90].  Frey et  al. [91] found that high FOXP3(+) Treg density was associated with early 
tumour  stage  and  independently  predicted  improved  disease-specific  survival  in  MMR-proficient 
CRCs, but not in MMR-deficient CRCs, though high Treg density correlated with absence of lymph 
node involvement and vascular invasion in the latter. They suggested that the role of Treg may differ 
according to the clinical stage and the MMR status of CRC. 
We have prepared live cell suspensions from enzymically disaggregated primary tumour tissue from 
CRC  patients  and  corresponding  normal  mucosa.  DotScan™  CRC  antibody  microarrays  and 
fluorescence multiplexing were used to profile the cells, and the CD3+ subset showed differential 
expression of HLA-DR, TCR, CD49d, CD52, CD49e, CD5, CD95, CD28, CD38 and CD71 in 
descending order of difference [21].  
4. Cancer Cells 
4.1. Tetraspanins and Potential Tetraspanin-Associated Proteins 
Tetraspanins are small transmembrane proteins, such as CD9, CD37, CD53, CD63, CD81, CD82, 
CD151 and tetraspanin 8, that are involved in a multitude of biological processes, including cell-cell 
adhesion, metastasis suppression and tumour progression [92–96]. Clinical studies have established a 
link between tetraspanin levels and prognosis and/or metastasis in cancer. The tetraspanins CD82 and 
CD9  mostly  suppress  tumour  progression;  their  expression  is  often  reduced  in  late-stage  human 
tumours and their down-regulation during CRC progression is associated with poor prognosis [97]. 
CD151  and  tetraspanin  8  support  tumour  progression;  increased  CD151  is  an  indicator  of  
poor prognosis.  
Tetraspanins interact with each other and other proteins that are required for their function, to form 
complexes in tetraspanin-enriched membrane domains (TEM) [95]. This has been referred to as the 
„tetraspanin web‟ [93,94]. The most prominent non-tetraspanin partners are integrins, e.g., CD29, 
CD49c, CD49d, CD49f and CD104; matrix metalloproteinases (MMP), e.g., MT1-
MMP (MMP14); members of the Ig superfamily, e.g., ICAM-1 (CD54) and VCAM-1 (CD106); as 
well as CD26, CD44, EpCAM (CD326), E-cadherin (CD324), beta-catenin (-catenin) and ADAM10. 
Some of these molecules have been implicated in tumour metastasis and poor patient prognosis. Int. J. Mol. Sci. 2011, 12                       
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Down-regulation of E-cadherin, the prime mediator of epithelial cell-cell adhesion [98], correlates 
with a strong invasive potential and poor prognosis in CRC [99–101]. High CRC cell staining for  
-catenin,  a  binding  partner  of  E-cadherin  [102],  is  independently  associated  with  better  patient 
survival  [103]. In contrast,  membranous  expression of  -catenin, together with low E-cadherin, is 
associated with CRC tumour progression, and may be an independent prognostic factor for poor patient 
outcome [104]. 
Absence of CD49c correlates with reduced overall and disease-free survival compared to patients 
with CD49c+ CRC [105]. CD29 is commonly down-regulated in CRC compared to normal intestinal 
mucosa [22,106,107], and this has been correlated with invasion and metastasis [108]. However, there 
is  little  evidence  for  correlation  between  CD29  levels  and  patient  outcome,  possibly  because  
up-regulation of CD29 has also been correlated with lymph node metastasis and depth of invasion in 
CRC [106]. The association of CD104 with members of the tetraspanin web also appears to support 
tumour cell motility and liver metastasis [109]. 
CD44 over-expression in CRC is generally considered to be an unfavourable prognostic factor for 
overall  survival,  though  this  may  depend  on  the  isoform.  CD44  variant  6  (CD44v6)  expression 
correlates with poor prognosis [110–112]. However, loss of CD44 significantly correlates with poor 
survival  when  associated  with  a  corresponding  loss  in  E-cadherin,  especially  in  Stage  II  CRC, 
suggesting that CD44 and E-cadherin may have an inter-dependent role in suppressing invasion and 
metastasis  [113].  The  worst  prognosis  was  associated  with  low  E-cadherin  coupled  with  high  
MT1-MMP (MMP14) [113], itself associated with tumour invasiveness in CRC [114–116]. 
Low  numbers  of  CD54-expressing  tumour  cells  may  be  associated  with  a  shorter  disease-free 
survival [117]. The prognosis of patients with CD54-negative tumours is significantly poorer than 
those with CD54-positive tumours, suggesting that low CD54 expression is closely associated with 
metastasis  and  may  be  a  useful  indicator  of  prognosis  [118].  Infiltration  by  TILs  has  been  more 
frequently observed in the CD54-positive than in CD54 negative tumours.  
4.2. Epithelial-Specific Cell Adhesion Activation Molecule (EpCAM, TROP-1, CD326) 
EpCAM is a pan-epithelial differentiation antigen which promotes cell adhesion [119]. In normal 
epithelial tissues, increased EpCAM expression is associated with enhanced proliferation and a lower 
differentiation grade of epithelial cells. In the proliferative phase, EpCAM expression is associated 
with epithelial tissue remodelling. After cell proliferation, EpCAM expression declines and cellular 
differentiation commences [120].  
The  regulation  of  EpCAM  in  tumour  invasion  and  metastasis  has  previously  been  
reviewed [121–125]. In carcinogenesis, EpCAM over-expression is present during the early stages, but 
dramatically decreases during malignant transformation and progression. Over-expression of EpCAM 
reportedly correlates with biological aggressiveness and poor prognosis in CRC [126], possibly by 
promoting tumour immune evasion by strongly favouring T-helper cell type 2 (Th2) development that 
promotes growth of EpCAM-expressing tumors [127]. However, a reduction in surface expression of 
EpCAM  has also been associated with aggressive cancers and poor prognosis in CRC [120]. The 
hypothesis that loss of EpCAM expression may be involved in cancer metastasis is further supported Int. J. Mol. Sci. 2011, 12                       
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by the finding that EpCAM protein expression on circulating tumour cells (CTC) is reduced compared 
with primary and metastatic tumours [128].  
Using  a  monoclonal  antibody  to  detect  an  extra-cellular  epitope  of  EpCAM  in  rectal  tumours, 
Gosens et al. [120] found that decreased membranous EpCAM staining in the “budding” cells at the 
invasive tumour front was always accompanied by a focally infiltrating growth pattern, correlated with 
a significantly higher risk of local recurrence and indicated an elevated risk of distant recurrence. 
Importantly,  loss  of  membranous  EpCAM  coincided  with  increasing  cytoplasmic  staining  at  the 
tumour front (detected by polyclonal antibody), suggesting altered cellular localisation due to abnormal 
post-translational processing of EpCAM rather than reduced expression of this antigen. An alternative 
view is that regulated intra-membrane proteolysis results in the shedding of EpCAM‟s ectodomain and 
the nuclear translocation of its intracellular domain, resulting in mitogenic signal transduction [129].  
This decline in membranous EpCAM expression at the tumour front was associated with nuclear  
-catenin  localization  [120],  which  is  associated  with  reduced  cell–cell  adhesion  and  increased 
migratory potential [130]. It did not correlate with disease stage, but did correlate with lower tumour 
differentiation grade, and was strongly prognostic [120]. It was predominantly observed in budding 
tumour  cells  or  clusters.  Tumour  budding  is  a  term  used  to  describe  the  appearance  of  foci  of  
de-differentiated  cancer  cells  at  the  invasive  tumour  front  of  differentiated  adenocarcinomas,  i.e., 
epithelial-to-mesenchymal transition (EMT) [131–133], and is frequently linked to high-grade tumours, 
lymph node positivity, vascular and lymphatic invasion and local and distant metastases [134].  
Decreased membranous EpCAM staining throughout the tumour rather than just at the invasive 
margin also correlates with increased risk of local recurrence, but is not indicative of distant recurrence 
[120]. Interestingly, increased EpCAM expression has been linked to CRC progression when it is 
associated with claudin-7 and recruited into TEM where it complexes with CD44v6 and tetraspanin 8 
[135,136]. This complex formation may facilitate metastasis by preventing EpCAM-mediated cell-cell 
adhesion and promoting migration, proliferation, apoptosis resistance and tumourigenicity. 
4.3. Mucins, Carbohydrates, Lectins 
Cancer cells, especially adenocarcinomas, tend to over-express mucins or express aberrant forms of 
mucins, the function and significance of which have been reviewed [137–139]. In CRC, high mucin 
content  has  been  associated  with  more  aggressive  phenotype  and  poorer  prognosis  [140].  CD227 
(MUC1), a membrane-associated mucin that displays altered O-glycosylation patterns in carcinomas, 
presents as an independent prognostic factor of CRC [141,142]. MUC1-Tn epitope becomes exposed 
during  malignant  transformation  to  adenocarcinoma  and  is  associated  with  poor  clinical  outcome 
[143]. CD175s (sialosyl-Tn) can modulate a malignant phenotype inducing a more aggressive cell 
behaviour, and is associated with poor clinical outcome [144]. MUC2 has been associated with less 
aggressive  tumour  phenotypes  and  improved  survival  in  some  studies  [61,145],  although  reverse 
findings have also been reported [146]. 
CD15s (Sialyl-Lewis
x, sLe
x) has an important role in defining the invasion and metastasis of human 
CRC;  high  level  expression  has  been  significantly  correlated  with  metachronous  metastases  after 
surgery  and  poor  prognosis  [147–150].  The  incidence  of  CD15s  positive  primary  tumours  was 
correlated with the depth of tumour invasion, lymph node metastasis, lymphatic invasion, and the Int. J. Mol. Sci. 2011, 12                       
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disease stage [150]; but Baldus et al. [141] did not find CD15s to be an independent prognostic factor 
of CRC. 
Sialyl-Lewis
a (sLe
a; CA 19-9), a mucin epitope whose levels in CRC correlate with overall survival 
and disease free survival, may serve as an indicator of metastatic potential [141,151]. It is believed that 
tumour  metastasis  and  cancer  cell  arrest  in  the  vasculature  is  facilitated  through  the  tethering  of 
circulating cancer cells to vascular endothelium through the interaction of molecules such as CD15s, 
CA 19-9 and CD44 variants on the tumour cell surface and selectins (CD62-P, -L and –E) expressed 
on endothelial cells, neutrophils, monocytes, NK cells or platelets [152–155]. 
Galectin-3,  a  lectin,  is  involved  in  neoplastic  transformation  and  tumour  progression  and  has 
demonstrated significant prognostic value, particularly in stages I and II CRC [141,156,157]. Low 
levels  of  galectin-3  expression  in  the  tumour  epithelium  are  associated  with  significantly  better 
prognoses than those characterized by high levels [158]. Galectin-3 up-regulates MUC-2 expression 
[159],  and a functional link has  been demonstrated between galectin-3, MUC-2 and metastasis in 
animal models [160,161]. However, these findings contradict other reports of an inverse relationship 
between MUC2 expression and tumour aggressiveness [61,162]. 
4.4. Carcinoembryonic Antigen (CEA) Family  
The  best  known  member  of  this  group  is  carcinoembryonic  antigen  (CEA;  CD66e),  which  is  
up-regulated  relative  to  normal  intestinal  mucosa  in  94%  of  CRC  samples  [163].  However,  the 
significance of CEA over-expression in CRC as a prognostic marker remains controversial. Despite 
several reports supporting a possible correlation between CEA expression in CRC and tumour spread 
or patient survival [164–166], no definitive correlation has been established [163,167] and CEA has 
found little utility as a prognostic marker. However, the expression of CEA by disseminated tumour 
cells isolated from intra-peritoneal lavage was found to strongly correlate with advanced tumour stages 
and  an  extremely  poor  prognosis  [168],  consistent  with  the  suggestion  that  CEA  may  enhance 
metastasis by functioning as an attachment factor for disseminated CRC cells [169]. 
CD66a  (CEACAM1)  and  CD66c  (CEACAM6)  are  also  over-expressed  in  58%  and  55%  of 
patients, respectively [163]. While no prognostic significance has been associated with CD66a, the 
over-expression of CD66c was found to be significantly associated with worse prognosis in a group of 
patients who received peri-operative FU-based chemotherapy [163]. CD66c has also demonstrated a 
role  in  tumour  cell  migration,  invasion  and  adhesion,  and  formation  of  distant  metastases  [170].  
CEA-related cell adhesion molecule 7 (CEACAM-7) is down-regulated in rectal cancers relative to 
normal mucosa and independently predicts recurrence-free survival for stage II rectal cancers [171]. 
4.5. Annexins 
Annexins A1, A2, A4 and A11 are expressed at higher levels in CRC than in normal colon, and 
have been implicated in tumour development and progression [172]. Over-expression of Annexins A4 
and A11 [172], Annexin A2 (Annexin II) [173] and Annexin A5 [174] may serve as markers of poor 
prognosis in patients with CRC.  Int. J. Mol. Sci. 2011, 12                       
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4.6. Claudins 
Claudin-1 and Claudin-4, transmembrane proteins important for tight junction formation in normal 
mucosal epithelial cells [175], are both up-regulated in CRC compared to normal mucosa, and this  
up-regulation is associated with down-regulation of E-cadherin and significant disorganisation of tight 
junction  fibrils  [176].  The  over-expression  of  claudin-1  and  -4  occurs  not  only  in  the  plasma 
membrane, but also in the cytoplasm [176], and its function in CRC is not yet defined. However, loss 
of claudin-1 expression is a strong predictor of disease recurrence and poor patient survival in stage II 
CRC [177], while a decrease in claudin-4 at the invasive front in CRC has been associated with cancer 
invasion and metastasis [178]. 
4.7. Chemokine Receptors 
Expression of the chemokine receptors CXCR3 [179,180] and CXCR4 (CD184) [181,182] has been 
associated with metastasis and poorer patient prognosis in CRC. Stroma-derived chemokines such as 
stromal cell derived factor-1 (a ligand of CXCR-4), may induce growth and metastatic progression of 
tumours by modulating proliferation, survival and homing, through chemokine receptors expressed on 
cancer initiating cells [183]. In contrast, chemokine receptor 5 (CCR5) expression has been associated 
with non-metastatic CRC and increased CD8
+ T-cell infiltration [184]. 
4.8. Growth Factor Receptors 
Epidermal growth factor receptor (EGFR) plays an important role in the biology of CRC [185] and 
is being used as a target for therapeutic antibodies in CRC patients with unmutated KRAS genes, but 
not in those with KRAS gene mutations which cause resistance [186,187]. However, despite reports 
indicating  its  value  as  a  prognostic  marker  [188,189],  its  potential  has  not  been  realised  [190]. 
Although patients with EGFR expression have a higher risk for disease recurrence compared to those 
with  EGFR  negative  tumours,  there  appears  to  be  no  relationship  between  EGFR  expression  and 
overall survival [191,192]. 
A significant  correlation  has  been demonstrated between insulin  growth  factor receptor (IGFR) 
expression levels (membrane plus cytoplasmic) and lymph node metastasis in CRC patients, especially 
when analysed in combination with vascular endothelial growth factor (VEGF) and VEGF-C [193]. 
Although  cytoplasmic  over-expression  of  human  epidermal  growth  factor  receptor  2  (CD340,  
HER-2/neu, ErbB2) is reported to be an independent prognostic indicator in CRC [194], membranous 
expression of this protein shows no prognostic significance [195]. Membranous expression of receptor 
tyrosine-protein kinase ErbB4, however, has recently been reported as an independent prognostic factor 
for recurrence in CRC patients after radical surgery [196]. 
Hepatocyte  growth  factor  receptor  (Met)  expression  correlates  with  poor  overall  survival  in 
advanced stages of CRC [197]. In stage I and II patients, however, membranous Met alone does not 
appear to be a significant predictor of patient outcome, although the membranous to cytoplasmic Met 
ratio correlates with survival [198]. Int. J. Mol. Sci. 2011, 12                       
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4.9. Death Receptors (DR) and Ligands 
The roles of death receptors and their ligands in cancer onset, progression and therapy have been 
reviewed [199]. Low expression of death receptor 4 (DR4; TRAILR1; CD261) has been linked to poor 
prognosis in CRC [200], consistent with a tumour suppressor role for DR4 and its ligand, tumour 
necrosis factor related apoptosis-inducing ligand (TRAIL). However, TRAIL has shown no prognostic 
significance in several studies [201,202] and has even correlated with worse overall survival in stage II 
and III CRC patients [203]. Interestingly, high DR4 expression has also been associated with worse 
disease-free and overall survival in stage III adjuvant-treated CRC patients [202]. These findings are 
consistent with the proposed existence of an alternative TRAIL signalling pathway in TRAIL-resistant 
cells, which leads to cancer promotion rather than inhibition [204,205]. The prognostic significance of 
the up- or down- regulation of these molecules may therefore vary in different patient sub-groups. 
Loss of CD95 (Fas) in tumour cells is related to adverse prognosis and maybe an independent 
prognostic factor in CRC [206]. Fas-ligand (CD178; CD95L; FasL) expression, however, correlates 
with lymph node involvement and distant metastases in CRC [207]. It has been suggested that the  
up-regulation  of FasL in  CRC cells  can induce apoptosis  of Fas-expressing T lymphocytes in the 
tumour [208]. Low Fas and high FasL maybe a useful indicator of lymph node metastases and poor 
prognosis in CRC [209].  
4.10. Major Histocompatibility Complex (MHC)  
The major histocompatibility complex (MHC) codes for human leukocyte antigens Class I (HLA-A, 
-B, -C) and Class II (HLA-DR, -DQ, -DP). Better prognosis correlates with the down-regulation of 
Class I antigens [210,211] and strong HLA-DR expression [212,213] on CRC cells.  
4.11. Other Protein Markers in CRC 
The A33 antigen is found in 95% of primary and metastatic CRC and also in the normal intestinal 
mucosa  [214].  A33  is  a  promising  target  for  immunotherapy  [215,216]  and  radioimmunotherapy 
[217,218] of CRC, but A33 levels have not been associated with prognosis.  
CD10 expression in CRC correlates with liver metastasis [219–221] and with the development and 
progression of CRC [162], but its prognostic significance in CRC has not been confirmed [222]. CD13 
(aminopeptidase N; APN) is involved in cell motility and angiogenesis, and CD13 expression may be a 
useful indicator of a poor prognosis for node-positive patients with colon cancer [223]. Membrane 
complement resistance factors CD55 and CD59 have been reported as markers of tumour aggression, 
and have been associated with reduced survival in CRC patients [224,225]. CD55 acts as a cellular 
ligand for CD97; strong CD97 expression by tumour cells at the invasive front has been correlated with 
a higher clinical stage and increased lymph vessel invasion compared to cases with uniform CD97 
staining throughout the tumour [226]. 
Membranous  expression  of  the  cell  adhesion  molecule  CD166  (ALCAM),  a  member  of  the 
immunoglobulin  superfamily,  has  been  correlated  with  significantly  shorter  survival  time  in  CRC 
patients  [227].  Cell  adhesion  molecule  CD171  (L1)  expression  is  also  associated  with  tumour 
progression and poor prognosis in CRC patients [99,228], and has been used, in combination with  Int. J. Mol. Sci. 2011, 12                       
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E-cadherin and membranous -catenin, to identify stage II patients who may benefit from adjuvant 
chemotherapy [104].  
Deleted in colorectal cancer protein (DCC) has been proposed as a putative tumour suppressor, and 
loss  of  DCC  expression  has  been  associated  with  poor  prognosis  and  risk  of  metastasis  [229]. 
Expression of DCC is a strong positive predictive factor for survival in CRC [230,231].  
Several  novel  membrane  proteins  have  recently  been  identified  in  CRC.  ATP-binding  cassette  
sub-family G member 5 (ABCG5) is a membrane protein involved in efflux transport of cholesterol. 
ABCG5 expression in tumour buds has recently been associated with significantly poorer prognosis in 
node-negative CRC patients [134]. ATP11A is an integral membrane ATPase, probably involved with 
the transport of ions such as calcium across membranes. Patients with high ATP11A expression have 
shown poorer disease-free survival compared to those with low expression, indicating that an increase 
in ATP11A expression may be an independent predictor of metastasis in CRC patients [232]. 
5. Colorectal Cancer Stem Cells (CSC) 
Cancer stem cells have been identified in several human malignancies, including CRC, and are 
believed to drive tumour initiation, progression and metastasis [233–238]. Tumour buds, discussed 
above, appear to have many features of CSC, and the possibility that a sub-population of tumour buds 
may represent malignant stem cells is an open question requiring further investigation [133]. 
The presence of a sub-population of CD26+ CSC in primary CRC tumours was found to predict 
distant metastases on follow-up [239]. These cells were associated with enhanced invasiveness and 
chemoresistance. High EpCAM expression was also associated with oncogenic potential in CSC [122], 
and CD166 (ALCAM) was found to be differentially expressed on EpCAM
high/CD44
+ CSC [240]. 
Other CSC markers, CD133 and CD24, correlated with invasiveness and differentiation in CRC, while 
CD44  expression  was  related  to  tumour  burden  [241].  No  correlation  was  found  between  the 
expression of these three markers and patient survival [241], but others have shown that the combined 
evaluation of CD133, CD166 and CD44 could be used to identify high and low survival among stage I 
and II CRC patients [242]. Although CD133+ cells have demonstrated CRC initiating potential [243], 
CD133 expression may not be restricted to cancer-initiating cells [244]. In addition, highly metastatic 
CD133- sub-populations of cancer-initiating cells have been identified in a human CRC xenograft 
model, suggesting that CD133+ tumour cells might give rise to a more aggressive CD133- subset 
during the metastatic transition [244]. 
CD200 (OX2) is a membrane glycoprotein that induces an immuno-regulatory signal through its 
receptor (CD200R), leading to the suppression of T-cell-mediated immune responses. CD200 has been 
associated  with  tumour  progression  and  poor  prognosis  in  several  cancers  [245,246]  and  is  over-
expressed in CRC with markers for CSC [247], suggesting that tumour-initiating CSC may evade 
immune system detection through CD200-induced suppression of T-cell-mediated immune responses.  
6. CRC Translational Proteomics Research 
A number of proteomic studies on CRC tissues have identified differentially expressed proteins 
from  whole  tissue  samples  of  CRC  and  paired  normal  mucosa  [8,16,248–252].  In  other  studies, 
enrichment for specific sub-populations of cells has been performed using techniques such as laser Int. J. Mol. Sci. 2011, 12                       
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micro-dissection [253,254], fluorescence activated cell sorting (FACS) [240] or antibody-conjugated 
magnetic beads [240,255]. Interpretation of results is complicated by the fact that different methods 
have  been  employed  for  sample  preparation,  antigen  detection  and  protein  quantification.  For  
antibody-based detection methods, the choice of monoclonal antibody is important, as differences in 
staining  may  reflect  changes  in  epitope  structure  due  to  mutations,  alternative  splicing  or  post 
translational modifications, rather than up- or down-regulation of protein expression. In addition, some 
changes  in  protein  activities  during  disease  progression  may  correlate  with  altered  sub-cellular 
localisation of proteins [120]. Thus the use of different methods of protein quantification may lead to 
conflicting results. 
Methods  used  for  membrane  proteomics  in  cancer  biomarker  discovery  have  been  previously 
reviewed [26]. Due to the hydrophobicity of membrane glycoproteins and their relatively low levels 
compared to soluble intracellular proteins [256], the identification and validation of novel differentially 
expressed surface markers in CRC has been limited. Membrane fractions from patient CRCs have been 
analysed  using  two-dimensional  fluorescence  difference  gel  electrophoresis  (2D-DIGE)  saturation 
labelling followed by MALDI-TOF-TOF mass spectrometry, with identification of 23 proteins, many 
classified as membrane or membrane-associated [5]. Others have been identified from membrane CRC 
fractions by iTRAQ [248]. Although approaches such as 2D-DIGE and mass spectrometry have led to 
the  discovery  of  a  number  of  differentially  expressed  proteins  in  CRC  [5–8,10–12,257,258],  the 
prognostic significance of these molecules and their contribution to cancer growth and metastasis has 
not always been easy to establish. Hence very few of these proteins have found clinical utility either as 
prognostic markers or therapeutic targets.  
Proteomic  methodologies  and  their  application  in  CRC  research  have  been  reviewed,  and  the 
limitations of traditional approaches for cancer biomarker marker discovery and future challenges have 
been  discussed  [259–261]. It  has  been suggested  that multiple markers will be required to enable 
reliable sub-classification of cancers [262–264]. The use of immunohistochemistry for analysis of CRC 
tissue sections for multiple potentially prognostic/predictive markers [141,265,266] has the advantage 
of  revealing  antigen  location;  however  the  method  is  relatively  low  through-put,  expensive,  
labour-intensive, and quantification is difficult. The use of tissue microarrays enables analysis of a 
large number of samples simultaneously, but the number of antigens that can be detected in a single 
assay is limited [267]. 
The  DotScan™  CRC  antibody  microarray  allows  rapid  immunophenotyping  for  122  surface 
antigens on a population of disaggregated live tumour cells in suspension, requiring 4 ×  10
6 cells per 
assay. Density of cell binding per antibody dot depends on the proportion of positive cells in the 
population,  level  of  antigen  expression  and  affinity  of  the  antibody.  Figure  1  shows  optical  and 
fluorescent binding profiles for a CRC sample from a stage II patient. The optical binding pattern 
reflects the immunophenotype of the mixed cell population, while the CD3-PE and EpCAM-Alexa 
Fluor 647 staining detect T-cells and cancer/epithelial cells, respectively. The limit of detection is 
approximately 1 cell in 10 for the optical scans, while the sensitivity of fluorescent scans is four times 
higher.  We  have  demonstrated  sub-types  of  CRC  based  on  hierarchical  clustering  of  microarray 
patterns [22] that may provide prognostic information when data are retrospectively analysed with 
patient outcomes. This study is ongoing. With the addition of antibodies against newly discovered Int. J. Mol. Sci. 2011, 12                       
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markers of CRC, this method could be used to correlate cell binding densities with disease stage, 
invasion, metastasis and patient outcome, and also for finding multiple-marker signatures allowing 
sub-classification of CRC. 
Figure 1. Binding patterns of a disaggregated stage II, poorly differentiated, CRC sample 
on a DotScan
TM CRC antibody microarray. (A) Antibody locations for duplicate arrays. 
Numbers  refer  to  CD  antigens;  other  abbreviations  are  TCR,  T-cell  receptor;  κ,  λ, 
immunoglobulin  light  chains;  slg,  surface  immunoglobulin;  DCC,  deleted  in  colorectal 
cancer protein; EGFR, epidermal growth factor receptor; FAP, fibroblast activation protein; 
HLA-A,B,C and HLA-DR, human leukocyte antigens A,B,C and DR, respectively; MICA, 
MHC  class  I  chain-related  protein  A;  MMP-14,  matrix  metallopeptidase  14;  PIGR, 
polymeric  immunoglobulin  receptor;  TSP-1,  thrombospondin-1;  Mabthera,  humanised 
anti-CD20. Alignment dots around microarray consist of a mixture of CD44 and CD29 
antibodies. (B) Optical scan; (C) and (D) fluorescence multiplexing using PE-anti-CD3 and 
Alexa 647-EpCAM, respectively.  
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Cell surface proteins are logical candidates as biomarkers and therapeutic targets; they enable a cell 
population to interact with other cells and soluble factors in the tumour microenvironment and reflect 
important genomic, epigenetic, transcriptional and translational changes during disease progression. As 
an alternative to the use of viable cells for analysis with the DotScan CRC antibody microarray, tumour 
cell-derived membrane fragments, microvesicles or microparticles could be used, as demonstrated with 
plasma-derived  microparticles  from  patients  with  cardiovascular  disease  [268].  This  alternative 
approach may facilitate the detection of potential prognostic biomarkers shed from cells located at the 
invasive front. Samples of the invasive front are required for routine pathology analysis and are not 
readily available for research purposes. 
Zlobec and Lugli [133] have described the invasive front of CRC as a dynamic interface between 
pro-  and  anti-tumour  factors.  Tumour  budding  at  the  invasive  front  promotes  progression  and 
dissemination of CRC cells into the vasculature and lymph nodes, while infiltrating immune cells, 
particularly cytotoxic T-cells, mount an immune response. The CD8+ lymphocyte / tumour-budding 
index appears to be an independent prognostic factor in CRC [269]. E-cadherin expression is lower in 
tumour budding sites than in the centre of the tumour [270], possibly contributing to reduced cell-cell 
adhesion at the tumour front. It has been suggested that a comparison of the pro- and anti-tumour 
factors at the invasive front could contribute to development of a prognostic score for patients with 
CRC [133], with proteomic analysis providing new prognostic markers for CRC.  
An alternative proteomic approach is the analysis of patient blood plasma or other biological fluids 
for CRC biomarkers [271], which include cancer-associated soluble factors, as well as tumour-derived 
microvesicles  [272–275].  Prefractionation  of  biological  fluids  is  required to  detect  low abundance 
proteins [276]. Lectin glycoarrays have been used to profile plasma for CRC biomarkers, with the 
identification of significant glycosylation changes associated with tumour progression [277–281]. 
In summary, the search continues for a reliable method of predicting metastatic spread and patient 
outcome after surgical resection of primary CRC. There is a general consensus that patterns of multiple 
biomarkers will be required; innovative approaches are needed to translate accumulating data into a 
useful  method for sub-classifying CRC patients  for disease stage and those likely to benefit from 
available  treatments.  Further  progress  in  cell  surface  protein  discovery  will  supplement  new 
discoveries  provided  by  other  innovative  technologies,  such  as  metabolomics  [282,283],  study  of 
oncogenic  pathways  [30,31],  anti-sense  therapeutic  strategies  [9,284],  and  combined 
proteomics/genomics strategies [285]. 
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